
Neuland Laboratories Ltd. share price
NSE: NEULANDLAB · Healthcare
₹21,640.00 +2.67%
Closing price data, updated 17 Nov 2026. 52-week range: -10.7% from high, +88.2% above low.
Price₹21,640.00
Market cap₹27,764 Cr
P/E61.4
P/B13.68
ROE21.4%
ROCE22.9%
Debt / equity0.16
Dividend yield0.00%
EPS₹352.73
Book value₹1,582.02
Operating margin25.4%
Dipscan score56 / 100
Share: WhatsAppX / TwitterTelegram
Neuland Laboratories Ltd. shareholding pattern
As of Sep 2026: Promoters 32.26%, FIIs 21.93%, DIIs 16.26%, Government 0.00%, Public 22.47%, Others 7.08%.
| Holder | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Promoters | 32.26% | 32.62% | 32.63% | 32.63% | 32.64% | 32.68% |
| FIIs | 21.93% | 21.08% | 20.46% | 20.90% | 20.60% | 21.69% |
| DIIs | 16.26% | 16.51% | 15.84% | 14.71% | 13.54% | 11.57% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.40% | 0.40% |
| Public | 22.47% | 22.88% | 23.84% | 24.31% | 24.72% | 25.55% |
| Others | 7.08% | 6.91% | 7.22% | 7.45% | 8.09% | 8.12% |
| No. of Shareholders | 49,741 | 44,340 | 46,304 | 46,187 | 44,393 | 42,419 |
As filed by the company with the exchanges.
Returns
| 1 day | 1 week | 1 month | 3 months | 6 months | 1 year |
|---|---|---|---|---|---|
| +2.67% | +9.85% | +7.13% | -6.75% | +29.74% | +25.87% |
Growth
| Sales growth, 3 years | +18.5% |
| Sales growth, 5 years | – |
| Profit growth, 3 years | +30.6% |
| Profit growth, 5 years | – |
| Latest quarter sales vs last year | -12.6% |
| Latest quarter profit vs last year | -46.7% |
Strengths and weaknesses
Strengths
- Company is expected to give good quarter
- Company has delivered good profit growth of 38.5% CAGR over last 5 years
Weaknesses
- Stock is trading at 13.7 times its book value
- Promoter holding has decreased over last quarter: -0.36%
Peers in Healthcare
| Company | Price | Market cap | P/E | ROE | 1 year |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | ₹1,867.50 | ₹4,48,076 Cr | 40.9 | 14.7% | +8.8% |
| Divi's Laboratories Ltd. | ₹11,080.00 | ₹2,94,139 Cr | 87.5 | 16.2% | +69.4% |
| Torrent Pharmaceuticals Ltd. | ₹4,691.20 | ₹1,78,438 Cr | 84.0 | 27.1% | +22.6% |
| Apollo Hospitals Enterprise Lt | ₹8,771.00 | ₹1,26,114 Cr | 56.2 | 21.9% | +16.9% |
| Laurus Labs Ltd. | ₹2,220.00 | ₹1,19,949 Cr | 89.5 | 18.2% | +125.2% |
| Zydus Lifesciences Ltd. | ₹1,192.00 | ₹1,18,902 Cr | 28.4 | 19.7% | +27.0% |
| Dr. Reddy's Laboratories Ltd. | ₹1,377.90 | ₹1,14,778 Cr | 41.0 | 12.1% | +13.7% |
| Cipla Ltd. | ₹1,394.50 | ₹1,12,658 Cr | 38.9 | 11.8% | -8.0% |
Frequently asked questions
What is the share price of Neuland Laboratories Ltd.?
Neuland Laboratories Ltd. (NEULANDLAB) last closed at ₹21,640.00 (+2.67% on the day).
What is the market cap of Neuland Laboratories Ltd.?
About ₹27,764 Cr.
What is the P/E ratio of Neuland Laboratories Ltd.?
The price-to-earnings ratio is 61.4, and return on equity is 21.4%.
Figures are calculated from company results and exchange prices and are for information only.